Paper Details

  1. Home
  2. Paper Details

[Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].

Author: , BulikováA, DoubekM, DulícekP, HlusíA, KissováJ, KorístekZ, OvesnáP, PavlíkT, PenkaM, PospísilováD, SchwarzJ

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This report provides an overview of anagrelid use in the Czech Republic for treating thrombocythaemia associated with chronic myeloproliferative disorders, based on data from the Register of Patients Treated with Thromboreductin. The report highlights the increasing use of anagrelid in combination therapies and notes a trend towards earlier diagnosis, resulting in fewer pre-treatment symptoms. Although treatment response is generally good, complications still occur in a significant percentage of patients.
Paper Details　
Original Abstract of the Article :
In the Czech Republic, anagrelid is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders for treatment ofthrombocythaemias associated with chronic myeloproliferative disorders--mainly essential thrombocythaemia and, regularly, reports are being presented f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20681462

データ提供：米国国立医学図書館（NLM）

Essential Thrombocythaemia and Other Myeloproliferative Disorders: Anagrelid Treatment

The field of hematology is always seeking effective ways to manage myeloproliferative disorders, a group of blood cancers that affect the bone marrow. This study delves into the use of anagrelid, a medication used to treat thrombocythaemia, a condition characterized by an abnormally high number of platelets in the blood.

Anagrelid: A Potential Treatment for Thrombocythaemia

The study provides insights into the use of anagrelid, also known as Thromboreductin, in patients with essential thrombocythaemia and other myeloproliferative disorders. The data suggest that anagrelid can effectively reduce platelet count and manage the associated risks. Think of anagrelid as a skilled desert navigator, guiding the body's blood system back to a balanced state.

Thrombocythaemia: A Potential Risk Factor

Thrombocythaemia, while often asymptomatic, can increase the risk of blood clots and bleeding. Early diagnosis and appropriate treatment are crucial to prevent complications and improve quality of life. Navigating the desert of hematological disorders requires careful monitoring and timely intervention.

Dr.Camel's Conclusion

This study highlights the importance of ongoing research and data collection in the field of hematology. The use of anagrelid in the management of thrombocythaemia provides a promising option for patients with myeloproliferative disorders. It's essential to continue exploring innovative treatments and optimize patient care as we continue to journey through the complex landscape of blood disorders.

Date :
  1. Date Completed 2010-11-10
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

20681462

DOI: Digital Object Identifier

20681462

Related Literature

Article Analysis
・Effects of anagrelide
SNS
PICO Info
in preparation
Languages

Czech

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.